To further assess the usefulness of @entity2847 in treatment of @entity161 seven inpatient chronic schizophrenics with acute exacerbation who had failed to respond to four weeks of antipsychotic therapy were treated with @entity2847 2.5 mg daily for a treatment duration varying from one dose to four weeks while their antipsychotic dose was continued unchanged. Mean age of @entity1 was 38.9 +/- 11.6 years and mean number of prior @entity146 hospitalizations was 12.0 +/- 7.2. @entity1 were rated with the Brief Psychiatric Rating Scale prior to the first @entity2847 dose, at 24 hours after dosage initiation, and at weekly intervals. One @entity1 showed clinically significant improvement in both positive and negative @entity161 . One @entity1 showed slight improvement in unusual thought content, and four @entity1 were clinically unchanged. One @entity1 significantly worsened after the first dose. Factors possibly contributing to response and non-response are discussed. This is a report of an open study in 7 @entity1 . It is the only report of @entity2847 treatment in @entity1 previously shown unresponsive to antipsychotics and whose antipsychotics dose was held constant throughout the study. Addition of @entity2847 to the antipsychotic regimen remains an unproven treatment approach which may be considered only in @entity1 refractory to or inadequately controlled with antipsychotics.

@entity2847 in augmentation of antipsychotic response in chronic XXXX : a negative pilot report.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity2847 :: ('MESH:D001971', 'Chemical') :: ['bromocriptine'] @entity161 :: ('MESH:D012559', 'Disease') :: ['schizophrenia', 'schizophrenic symptoms'] @entity146 :: ('MESH:D001523', 'Disease') :: ['psychiatric']
@entity161 :: (MESH:D012559,Disease) :: ['schizophrenia']
